Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic growth hormone secretagogue receptor agonist
GHRP-2, also called pralmorelin, is a synthetic ghrelin-receptor agonist that reliably triggers acute growth-hormone release. It has diagnostic use in Japan, but human evidence does not establish it as a treatment for muscle gain, fat loss, recovery, sleep, or longevity.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
GHRP-2, also called pralmorelin, is a synthetic compound that activates a ghrelin-like signal and can prompt the pituitary gland to release growth hormone.
Researchers have used that predictable short-term hormone response to study growth-hormone physiology and diagnostic testing. They have also asked whether the compound changes appetite or releases other pituitary hormones.
Several small controlled human studies consistently show an acute growth-hormone response. A seven-person study also found increased food intake, and other work shows that the response is not fully selective because additional hormones can change.
Long-term clinical benefit, repeated-use safety, appetite and glucose consequences, desensitization, body-composition outcomes, sleep, recovery, and product quality remain unresolved. Acute hormone release is not evidence of muscle gain, fat loss, or longevity.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A small controlled crossover study examined short-term hormone and food-intake responses in healthy men.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
The record is human but focused on acute endocrine testing.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Confidence is low for therapeutic outcomes because they were not tested.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: Only seven participants were studied over 270 minutes. An acute appetite and hormone response cannot establish chronic weight, body-composition, recovery, sleep, or safety outcomes. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Multiple small human endocrine challenge studies consistently demonstrate acute GH release; diagnostic accuracy research supports a narrow testing context.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Long-term therapeutic benefit and safety, metabolic and glucose effects, appetite consequences, HPA-axis and prolactin effects, desensitization, and unapproved product quality.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
That makes it useful as an endocrine challenge, not automatically as a therapy.
Country-specific diagnostic use is not FDA approval or evidence for chronic self-administration.
Appetite stimulation may run counter to some body-weight goals.
Human studies also report prolactin, ACTH, and cortisol responses.
The human record is dominated by endocrine testing.
Mechanisms
GHRP-2 activates GHSR1a and stimulates pituitary growth-hormone release through hypothalamic and pituitary pathways. Small human studies support its use as an endocrine challenge, including diagnostic evaluation of severe adult growth-hormone deficiency in Japan. Acute studies also show increased food intake and nonselective prolactin, ACTH, and cortisol responses. These endocrine effects do not establish sustained body-composition, performance, recovery, sleep, or anti-aging outcomes. No FDA-approved pralmorelin product or modern long-term therapeutic outcomes program was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled endocrine challenge and diagnostic-accuracy study
Adults evaluated for growth hormone deficiency
The test produced GH responses useful for a narrow diagnostic context.
Study administration: GHRP-2 stimulation test
Limitations: Diagnostic performance does not establish chronic treatment benefit.
Placebo-controlled crossover infusion study
Seven healthy men
Participants consumed about 35.9% more food during GHRP-2 exposure and GH increased.
Study administration: Subcutaneous GHRP-2 infusion or saline
Limitations: Seven participants and an acute laboratory meal do not define chronic appetite or weight effects.
Comparative acute hormone-response study
Healthy adults
GHRP-2 stimulated GH but also increased prolactin, ACTH, and cortisol.
Study administration: GHRP-2 or hexarelin
Limitations: Acute hormone changes do not establish clinical benefit or long-term safety.
Review of human pharmacology and diagnostic development
Human endocrine-study populations
The literature supports an endocrine secretagogue and diagnostic role, not a broad therapeutic outcomes use.
Study administration: GHRP-2 challenge procedures
Limitations: A review cannot substitute for long-term randomized therapeutic trials.
Safety snapshot
No source-qualified adverse-event pattern is represented in the current record.
Evidence boundaryHuman exposure is present, but the record is not detailed enough to characterize a reliable adverse-event pattern.
The current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryNot FDA approved — historical human endocrine and diagnostic evidence Long-term therapeutic benefit and safety, metabolic and glucose effects, appetite consequences, HPA-axis and prolactin effects, desensitization, and unapproved product quality.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2007-07-01 · PMID 17609397 · DOI 10.1530/EJE-07-0066
2005-03-01 · PMID 15699539 · DOI 10.1210/jc.2004-1719
2004-07-01 · PMID 15230633
1997-09-01 · PMID 9285939